ACTICOR BIOTECH announced the publication of phase 1b/2a clinical results of ACTIMIS study in The Lancet Neurology Journal. The manuscript is entitled: Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a phase 1b/2a randomized, placebo-controlled, trial. The ACTIMIS clinical trial evaluated glenzocimab in combination with the reference treatment (thrombolysis with or without thrombectomy) in patients presenting with an Acute Ischemic Stroke.

This publication displays the full analysis of ACTIMIS results. The key results presented in the manuscript are: Achievement of ACTIMIS primary endpoint, confirming the safety of glenzocimab in AIS patients; In phase 2a, glenzocimab 1000 mg, as add-on therapy to alteplase, was associated with reduced symptomatic intracerebral haemorrhage (0% vs 10%) and all-cause mortality (8% vs 21%) compared with placebo; Patients with the most severe strokes and at highest risk of intracranial haemorrhage might be the best responders in this study. The results of ACTIMIS were first presented during the European Stroke Organisation Conference (ESOC) in 2022.

Find here previous exchanges with Professor Mikael Mazighi MD, PhD who is the global study coordinator: The media presentation: As a reminder, the ongoing phase 2/3 clinical trial ACTISAVE has completed its recruitment in October 2023 with expected results in the second quarter of 2024.